Archeon Medical Raises $9 Million in Series A Funding
Archeon Medical, a France-based company specializing in advanced ventilation feedback devices for CPR, has announced the successful closure of a $9 million Series A funding round. The funding, which took place on October 6, 2026, was led by Newfund's HEKA fund, with participation from Eiffel Investment Group, UI Investissement's OSER BFC fund, Majycc Innovation Santé, and Karot Capital.
Company Overview
Archeon Medical is known for its EOlife system, which offers real-time feedback on ventilation during cardiac arrest treatments. This system is compatible with manual resuscitators such as the Ambu Bag and is designed to help medical teams improve resuscitation outcomes.
Use of Funds
The newly acquired funds are earmarked for the clinical validation of the EOlife system in the United States and its subsequent commercial expansion. This strategic move aims to solidify EOlife's position as a standard tool in emergency resuscitation efforts, providing critical data to enhance survival and neurological outcomes.
Leadership and Vision
Alban De Luca, CEO and Founder of Archeon Medical, emphasized the significance of this funding milestone, stating: "These resources allow us to generate clinical evidence at scale and turn EOlife into the new global standard for emergency resuscitation." Pierre-Edouard Saillard, COO and Cofounder, also plays a crucial role in steering the company's growth and operational strategies.
Investor Participation
The Series A funding round saw robust participation from a mix of new and existing investors. Led by Newfund’s HEKA fund, the round also included contributions from Eiffel Investment Group and UI Investissement’s OSER BFC fund, alongside existing backers Majycc Innovation Santé and Karot Capital.
Archeon Medical's strategic focus on enhancing emergency healthcare solutions positions it well for future growth and innovation, particularly in the critical area of cardiac arrest treatment.